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Abstract
Inhaled corticosteroids (ICSs) are the most effective anti-inflammatory agents available for the treatment of asthma
and represent the mainstay of therapy for most patients with the disease. Although these medications are
considered safe at low-to-moderate doses, safety concerns with prolonged use of high ICS doses remain; among
these concerns is the risk of adrenal suppression (AS). AS is a condition characterized by the inability to produce
adequate amounts of the glucocorticoid, cortisol, which is critical during periods of physiological stress. It is a
proven, yet under-recognized, complication of most forms of glucocorticoid therapy that can persist for up to 1
year after cessation of corticosteroid treatment. If left unnoticed, AS can lead to significant morbidity and even
mortality. More than 60 recent cases of AS have been described in the literature and almost all cases have
involved children being treated with ≥500 μg/day of fluticasone.
The risk for AS can be minimized through increased awareness and early recognition of at-risk patients, regular
patient follow-up to ensure that the lowest effective ICS doses are being utilized to control asthma symptoms, and
by choosing an ICS medication with minimal adrenal effects. Screening for AS should be considered in any child
with symptoms of AS, children using high ICS doses, or those with a history of prolonged oral corticosteroid use.
Cases of AS should be managed in consultation with a pediatric endocrinologist whenever possible. In patients
with proven AS, stress steroid dosing during times of illness or surgery is needed to simulate the protective
endogenous elevations in cortisol levels that occur with physiological stress.
This article provides an overview of current literature on AS as well as practical recommendations for the
prevention, screening and management of this serious complication of ICS therapy.
Background
Asthma is the most common chronic disease among the
young, affecting 10% to 15% of Canadian children and
adolescents [1-3]. It is also a major cause of pediatric
hospital admissions and emergency department visits
[4,5]. Despite significant improvements in the diagnosis
and management of asthma over the past decade, as well
as the availability of comprehensive and widely-accepted
national and international clinical practice guidelines for
t h ed i s e a s e[ 6 , 7 ] ,a s t h m ac o n t r o li nC a n a d ar e m a i n s
suboptimal. Approximately 50-60% of Canadian children
and adults have uncontrolled disease according to guide-
line-based asthma control criteria [8,9].
Inhaled corticosteroids (ICSs) are the most effective
anti-inflammatory medications available for the treat-
ment of asthma and represent the mainstay of therapy
for most patients with the disease. The current Cana-
dian standard of care is low-dose ICS monotherapy as
first-line maintenance therapy for most children and
adults with asthma [7]. Regular ICS use has been shown
to reduce symptoms and the need for rescue beta-ago-
nists, prevent exacerbations, improve lung function and
quality of life, and reduce hospitalizations and asthma-
related mortality [6,7,10-13].
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to those recommended in adults (see Table 1) [14]. At
low-to-moderate doses, ICSs are considered safe medi-
cations, and are generally not associated with clinically
significant adverse effects. Furthermore, studies have
shown that ICS treatment markedly reduces the need
for oral corticosteroids, which have been associated with
well-known serious adverse effects [15].
Although the side effects of ICSs are less frequent and
severe than those of oral corticosteroids, safety concerns
with these agents still remain, particularly when used at
high doses. Among these concerns is the risk of adrenal
suppression (AS) – a condition characterized by the
inability to produce adequate amounts of cortisol (a glu-
cocorticoid that is critical during periods of physiologi-
cal stress). AS is an under-recognized complication of
ICS therapy that, if left unnoticed, can lead to significant
morbidity and even mortality [16-19]. The purpose of
this review is to assist physicians and other healthcare
professionals in identifying patients who may be at risk
for AS, and provide practical recommendations for the
screening and management of this potentially serious
side effect of ICS therapy.
Adrenal Suppression (AS): Definition,
Pathophysiology and Clinical Presentation
Definition
Adrenal insufficiency is a condition in which the adrenal
glands are unable to produce adequate amounts of corti-
sol (a glucocorticoid responsible for maintaining blood
pressure, blood glucose and energy levels during times
of physiological stress, such as illness, surgery or injury).
It can result from any etiology (i.e., genetic, iatrogenic,
acquired), and may also be associated with other adrenal
hormone deficiencies, such as impaired aldosterone pro-
duction (see Table 2) [20].
AS is the most common cause of adrenal insufficiency,
and refers to decreased or inadequate cortisol produc-
tion that results from exposure of the hypothalamic-
pituitary-adrenal (HPA) axis to exogenous glucocorti-
coids (see Table 2) [20,21]. It is a proven, yet under-
recognized, complication of most forms of glucocorti-
coid therapy (e.g., inhaled, oral, intramuscular, intrana-
sal, intravenous) that can persist for up to 1 year after
cessation of corticosteroid treatment [16,22]. More than
60 recent cases of AS have been described in the litera-
ture [22,23]. Although the risk factors for the develop-
ment of this condition have not been clearly established,
increased dose and longer duration of glucocorticoid
therapy appear to be associated with an increased risk
[22]. In fact, the Pediatric Endocrine Society suggests
that AS be considered in all children who have received
supraphysiological doses of oral corticosteroids (>8-12
mg/m
2/day - hydrocortisone equivalent) for greater than
2 weeks [24]. AS is also considered to be an important
risk in children who require long-term treatment with
high-dose ICS therapy. Children who are being treated
for asthma often receive other forms of glucocorticoids
in addition to ICSs (i.e., intranasal, oral, intravenous)
and, therefore, the patients’“ total steroid load” must be
considered when evaluating the risk of AS.
If AS is left unrecognized and the body is subjected to
physiological stress, such as injury, surgery or a severe
infection, the condition can lead to an adrenal crisis (see
Table 2). Adrenal crisis is defined as severe, life-threa-
tening adrenal insufficiency characterized by severe
hypotension and/or hypoglycemia which may lead to
seizures and even coma [20,21,25-28]. Although it is
considered a rare consequence of AS, a retrospective
survey in the United Kingdom (UK) found that the fre-
quency of acute adrenal crisis in children using ICS
therapy was greater than previously expected [17].
Pathophysiology
The HPA axis is under circadian regulation and operates
in a negative feedback loop to regulate cortisol secretion
within the body. The hypothalamus releases corticotro-
pin-releasing hormone (CRH), with peak levels being
produced in the morning (around 6 am). CRH then sti-
mulates the release of adrenocorticotropic hormone
(ACTH) from the pituitary gland, which, in turn, stimu-
lates the adrenal glands to secrete cortisol. Cortisol has
Table 1 ICS starting doses for asthma therapy in children in Canada
ICS and inhaler device Minimum age licensed for
use
Low-moderate dose (μg/
day)
High-dose (μg/
day)
Beclomethasone dipropionate MDI (Qvar, generics) 5 years 100-150 BID 200 BID
Budesonide DPI (Pulmicort) 6 years 200 BID 400 BID
Budesonide Nebulizer (Pulmicort) 3 months 250-500 BID 1000 BID
Ciclesonide MDI (Alvesco) 6 years 100-200 OD 400 OD-BID
Fluticasone propionate MDI/DPI (Flovent HFA, Flovent
Diskus)
12 months 100-125 BID 250 BID
ICS: inhaled corticosteroid; MDI: metered dose inhaler; DPI: dry powder inhaler; BID: twice daily; OD: once daily
Adapted from Kovesi et al., 2010 [14]
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gland, which leads to decreased secretion of CRH and
ACTH and, in turn, reduced production and secretion
of cortisol. This negative-feedback loop allows the HPA
axis to tightly self-regulate cortisol levels in the body.
Exogenous glucocorticoids exert negative feedback in
the same manner as endogenous cortisol, leading to the
suppression of cortisol production and, subsequently,
adrenal insufficiency [29]. Since cortisol production is
critical during periods of physiological stress (i.e., illness
or surgery), its suppression by exogenous glucocorti-
coids can lead to significant morbidity (adrenal crisis)
and even mortality.
Clinical Presentation
The clinical presentation of AS is highly variable. Symp-
toms are often non-specific and may include: weakness,
fatigue, malaise, nausea, abdominal pain, poor weight
gain, and headache (see Table 2). In some cases, AS
may be associated with biochemical changes in the
absence of symptoms [21]. Decreased growth may also
be a clinical sign of AS and is often seen in children
with significant AS. However, growth suppression may
also be a primary side effect of ICS therapy or may
occur secondary to poor asthma control [30-34].
Therefore, decreased growth is neither a sensitive nor a
specific indicator of AS [35].
Given the non-specific nature of the symptoms of AS,
the disorder can often go unrecognized until physiologic
stress (e.g., simple gastroenteritis, minor upper respira-
tory tract infection, surgery) precipitates an adrenal cri-
sis. Many of the symptoms of these common stressors
are so similar to those of adrenal suppression that the
first signs of AS may go unnoticed, unless there is a
high level of suspicion and the families of patients at
risk are made aware of the possibility of this side effect.
The symptoms of adrenal crisis include: hypotension
and unexplained, acute hypoglycemia that often leads to
seizures, decreased consciousness, and even coma [21].
In children presenting with symptoms suggestive of
AS, it is important to rule out a primary cause of adre-
nal insufficiency (i.e., Addison’s disease). In primary
adrenal insufficiency, individuals usually have both
symptoms of glucocorticoid deficiency (consistent with
AS) as well as symptoms of mineralocorticoid deficiency.
Mineralocorticoids stimulate sodium reabsorption and
potassium excretion. Symptoms of mineralocorticoid
deficiency include salt cravings, volume depletion and
weight loss. Unlike AS, adrenal crisis associated with
mineralocorticoid deficiency is often associated with
hyponatremia and hyperkalemia [36,37]. Findings con-
sistent with mineralocorticoid deficiency should prompt
the physician to consider a primary cause of the
patient’s symptoms.
Testing
Several endocrine tests have been used for the screening
and diagnosis of AS. The insulin-induced hypoglycemia
test (IIHT) was once considered the gold standard for
the diagnosis of adrenal insufficiency, but is no longer
used in children due to the neurocognitive risks asso-
ciated with hypoglycemia. The standard-dose (250 μg)
ACTH stimulation test was previously the best available
test; however, a recent meta-analysis found the sensitiv-
ity of this test to be suboptimal when compared to the
newer, low-dose (1 μg) ACTH stimulation test [38].
Although these findings remain controversial in the
medical community, the low-dose ACTH stimulation
test is now considered by many to be the best test for
diagnosing AS in children. This test involves the intrave-
nous administration of 1 μg of cosyntropin followed by
the measurement of serum cortisol levels at baseline (0
min), 15-20 min and 30 min to assess the function of
the HPA axis. A peak cortisol level >500 nmol/L is con-
sidered a normal response; a peak level <500 nmol/L is
diagnostic of AS, with both a sensitivity and specificity
of approximately 90% [38-46]. Given the natural circa-
d i a nv a r i a t i o ni nc o r t i s o ls ecretion, the test should be
Table 2 Adrenal insufficiency, adrenal suppression (AS),
and adrenal crisis: definitions and symptoms [20,21]
Definition Signs/Symptoms
Adrenal insufficiency: Adrenal glands unable
to produce a sufficient amount of cortisol
secondary to ANY etiology (genetic,
iatrogenic, acquired); may be associated with
other adrenal hormone deficiencies.
► Weakness/fatigue
► Malaise
► Nausea
► Vomiting
► Diarrhea
► Abdominal pain
► Headache (usually in
the morning)
► Poor weight gain
► Poor linear growth
► Myalgia
► Arthralgia
► Psychiatric symptoms
Adrenal suppression (AS): Adrenal glands
unable to produce a sufficient amount of
cortisol secondary to exposure of the HPA
axis to exogenous glucocorticoids, leading to
suppression and, in turn, adrenal insufficiency.
► Weakness/fatigue
► Malaise
► Nausea
► Vomiting
► Diarrhea
► Abdominal pain
► Headache (usually in
the morning)
► Poor weight gain
► Poor linear growth
► Myalgia
► Arthralgia
► Psychiatric symptoms
Adrenal crisis: Severe, life-threatening adrenal
insufficiency; can occur with AS.
► Hypotension
► Hypoglycemia
(seizure, coma)
HPA: hypothalamic-pituitary-adrenal
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and specificity [47].
Although the low-dose ACTH stimulation test is cur-
rently the most sensitive and specific test for AS, a first
morning (08:00 am) cortisol measurement is often more
practical and is considered to be a reasonable first step
for the identification of cases of suspected AS, or for the
screening of children being treated with high-dose ICS
therapy. The specificity of this test approaches 100% if a
very low cut-off value (<85-112 nmol/L) is used; how-
ever, the sensitivity is poor (~ 60%) [48]. Although
higher cut-off values have been proposed, these have
been associated with poorer specificity [49].
If an abnormal value is noted, the low-dose ACTH sti-
mulation test should be performed to confirm the diag-
nosis. Given the poor sensitivity of the first morning
cortisol measurement, a normal value does not rule out
AS. Therefore, if the test result is normal, but the
patient is experiencing symptoms suggestive of AS, a
low-dose ACTH test is recommended.
Since cortisol levels decrease throughout the day, a
random cortisol measurement is not an adequate mea-
sure of AS in children. Other measures of adrenal insuf-
ficiency are available, such as the assessment of urinary
or salivary cortisol levels; however, these tests have not
been well-studied in children with AS [50-52].
Inhaled Corticosteroids (ICS): Pharmacokinetic
and Pharmacodynamic Differences and Drug
Interactions
Although the various ICSs available for the treatment of
asthma are believed to have similar clinical efficacy
when used at equivalent therapeutic doses, significant
differences in their pharmacokinetics (PK) and pharma-
codynamics (PD) exist which can impact their respective
safety profiles. These differences warrant careful consid-
eration when determining the benefits and risks of each
ICS medication in an individual patient, particularly as
they relate to the risk of systemic side effects such as
AS [53]. Table 3 provides an overview of the PK and PD
parameters that influence the safety of ICSs, such as oral
bioavailability, lung deposition, protein-binding, half-life
and systemic clearance [54].
In order to better understand the effect of PK and PD
parameters on safety, it is helpful to briefly review the
fate of an ICS (see Figure 1). Depending on the inhaler
device, approximately 10-60% of the administered ICS is
deposited into the lungs upon inhalation. In the lungs,
the ICS exerts its effect on inflamed tissue as soon as it
dissolves into the pulmonary lining and binds to intra-
cellular corticosteroid receptors. The remainder of the
drug that does not get absorbed into the lung (40-90%)
is deposited into the mouth and pharynx, where it has
the potential to exert local side effects, such as orophar-
yngeal candidiasis and dysphonia. If not rinsed out of
the mouth, this portion of the ICS dose may be swal-
lowed and subsequently absorbed into the gastrointest-
inal (GI) tract (note that the amount swallowed can be
reduced to as little as 10% through the use of a spacer)
[55,56]. Drug that is absorbed from the GI tract and
that escapes inactivation by first-pass metabolism in the
liver enters the systemic circulation unchanged, poten-
tially causing serious systemic side effects [53,57,58].
Oral Bioavailability
The oral bioavailability of an ICS refers to the portion of
the inhaled dose that is swallowed, escapes first-pass
metabolism in the liver, and is available for systemic
absorption (see Figure 1). Since the proportion of the
ICS dose that is absorbed orally increases the potential
f o rs y s t e m i cs i d ee f f e c t s ,i ti s advantageous for the oral
bioavailability of an ICS to be relatively low. The oral
bioavailability of the currently available ICSs varies
widely, from approximately <1% for ciclesonide and flu-
ticasone to 20-40% for beclomethasone (see Table 3)
[53,57,59-61].
Lung Deposition
Lung deposition refers to the amount of drug that enters
the lung and exerts an effect at the site of inflammation.
For ICSs to exert their optimal anti-inflammatory effect,
a high lung deposition is generally desirable. Several
Table 3 Pharmacodynamic (PD) and pharmacokinetic (PK) properties of the ICSs available for the management of
asthma in Canada[53,54]
ICS Oral bioavailability
(%)
Lung deposition
(%)
Particle size
(μm)
Protein-binding (% not
bound)
Half-life
(h)
Systemic clearance
(L/h)
Beclomethasone
dipropionate
20/40* 50-60 <2.0 13 2.7* 150/120*
Budesonide 11 15-30 >2.5 12 2.0 84
Ciclesonide <1/<1* 50 <2.0 1/1* 0.5/4.8* 152/228*
Fluticasone propionate ≤1 20 2.8 10 14.4 66
*active metabolite
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physical properties of the ICS; (2) the delivery device; (3)
particle size (discussed later); and (4) patient characteris-
tics such as inhaler technique, age, and asthma severity
[57,60]. As seen in Table 3, lung deposition is greatest
with ciclesonide and beclomethasone [54].
Particle Size
Particle size is an important determinant of the propor-
tion of ICS that is deposited in the lower airways rela-
tive to the oropharyngeal cavity. Ideally, to be deposited
in the bronchi and bronchioles, particles should be
between 1-5 μm. Larger particles (>5 μm) are likely to
be deposited into the oropharynx, while very small parti-
cles (<1 μm) will either be deposited in the upper air-
ways or, if drawn into the lower airways, will be
exhaled. Beclomethasone and ciclesonide delivered by
metered-dose inhaler (MDI) have the smallest particle
sizes among the available ICS medications [53,59].
Prodrugs
Ciclesonide and beclomethasone are prodrugs that are
inhaled as inactive compounds and then converted
into their active metabolites (des-ciclesonide and
17-monopropionate, respectively) by enzymes located in
the pulmonary epithelium [53,59]. Because prodrugs are
inactive until they reach the lung, they are believed to
be associated with fewer local side effects compared to
ICSs that are administered in their active form (e.g., flu-
ticasone and budesonide). In studies of ciclesonide,
bioactivation within the oropharynx was shown to be
very low, resulting in lower amounts of active drug in
the oropharyngeal region compared with budesonide
and fluticasone [62,63].
Plasma Protein-Binding
When an ICS binds to plasma protein (albumin) in the
systemic circulation, it is rendered pharmacologically
inactive. Therefore, a high degree of plasma protein-
binding is desirable to reduce the potential for systemic
side effects [53,57,59,60]. Protein binding levels of bude-
sonide, fluticasone and the active metabolite of cicleso-
nide (des-ciclesonide) have been shown to inversely
correlate with degrees of cortisol suppression [64]. Both
ciclesonide and des-ciclesonide are highly protein-bound
(99%) in the systemic circulation (see Table 3) and
have been shown to result in minimal suppression of
cortisol [65].
GI tract
Lung
Mouth and pharynx
Liver
Orally bioavailable
fraction
Absorption
from gut
First-pass
inactivation
Systemic
circulation
Complete absorption
from the lung
40 – 90 % 
Swallowed
(reduced by spacer
or mouth rinsing)
10 – 60 % 
Deposited in lung
Systemic
side effects
Figure 1 Schematic representation of the fate of an ICS. [53,58]Adapted from Derendorf et al., 2006 [53]; Derendorf, 1997 [58].
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The metabolism and excretion of an ICS are factors
contributing to the potential for systemic side effects. A
short-half life and high clearance rate reduce the expo-
sure of the ICS to the systemic circulation, thereby
improving the safety profile. The elimination half-lives
of the currently available ICSs range from 14.4 hours
with fluticasone to as little as 0.5 hours with des-cicleso-
nide (Table 3) [54].
After systemic absorption, ICSs are metabolized pri-
marily by the liver, and the clearance rate of most ICS
medications is typically similar to or somewhat lower
than the rate of hepatic blood flow (~90 L/h) (Table 3)
[53,57]. However, the systemic clearance of the active
metabolite of ciclesonide considerably exceeds hepatic
blood flow, indicating that additional mechanisms of
clearance by other organs are likely involved [59].
Drug Interactions
In addition to the PK and PD properties of ICS thera-
pies, it is important to note that clinically significant
drug interactions have been noted with a number of ICS
medications and potent inhibitors of cytochrome (CYP)
3A4 isozymes, such as ritonavir, ketoconazole, and itra-
conazole (Table 4 provides a list of the more potent
CYP3A4 inhibitors). Concomitant administration of itra-
conazole and budesonide, for example, has been asso-
ciated with a more than 4-fold increase in plasma
concentrations of budesonide given by inhalation. The
concomitant use of ritonavir and fluticasone has also
been shown to greatly increase plasma fluticasone con-
centrations, leading to cases of Cushing’ss y n d r o m ea n d
AS. Approximately 25 cases (15 adult and 10 pediatric)
of significant AS secondary to an interaction between
ritonavir and ICSs have been noted, and most (24 of 25)
have occurred with fluticasone. The vast majority of
these cases were receiving high ICS doses prior to
beginning the inhibitor, and Cushingoid appearances
were often noted within 2 weeks of starting ritonavir
therapy [66-70]. In 2004, the Health Products and Food
Branch of Health Canada posted a public health advi-
sory warning patients and healthcare professionals of
this serious drug interaction, and advised that the con-
comitant use of fluticasone and ritonavir be avoided,
unless the benefit to the patient outweighs the risk of
systemic corticosteroid side effects [71]. If ritonavir is
required, another ICS, such as low-dose budesonide or
beclomethasone, should be considered and used with
caution [72]. Clinicians should also consider the use of
lower ICS doses with coadministration of other CYP3A4
inhibitors (see Table 4) [54].
Effects of ICS Therapy on Adrenal Suppression
(AS): Review of the Evidence
Biochemical Evidence
Biochemical evidence of AS, which is often assessed
using an early morning cortisol measurement or the
low-dose ACTH stimulation test, is commonly found in
children receiving ICS therapy, particularly those using
high doses [25]. However, a high degree of inter-indivi-
dual susceptibility to AS has been noted and is likely
related to individual patient factors including asthma
severity. Biochemical evidence of AS is most commonly
seen with fluticasone, particularly at doses ≥500 μg/day.
In a study of 18 asthmatic children treated with approxi-
mately 500 μg/day of fluticasone, half of the subjects
studied had biochemical evidence of AS (as assessed by
the insulin tolerance test) up to 16 weeks after starting
fluticasone therapy [73]. Similar findings were noted in
a study of 34 children on high-dose ICS therapy who
were switched to either fluticasone 750 μg/day or beclo-
methasone 1500 μg/day. Twelve weeks after the switch,
abnormal low-dose ACTH test results indicative of AS
were noted in over 60% of patients in each treatment
group [74]. Paton et al. used the low-dose ACTH stimu-
lation test to assess adrenal function in 194 children
receiving ≥500 μg/day of fluticasone and found that
approximately 40% of these subjects had evidence of AS
[18].
One study of 16 healthy adults found doses of beclo-
methasone ≥1000 μg/day to be associated with signifi-
cant suppression of overnight urinary cortisol-to-
creatine ratio [75]. A 12-month observational study of
35 asthmatic children (aged 4-10 years) using ≥1,000
μg/day of budesonide (median = 1,600 μg/day) or
equivalent doses of fluticasone (median = 1000 μg/day)
for at least 6 months, found biochemical evidence of AS
(using the low-dose ACTH stimulation test) in 46% of
subjects [35]. However, AS appears to be rare on bude-
sonide doses of <400 μg/day, even with long-term
treatment. One study found no change in HPA-axis
Table 4 Examples of potent CYP3A4 inhibitors
Antibiotics Quinupristin (Synercid)
Antidepressants Fluvoxamine (Luvox)
Nefazodone (Serzone)
Antifungal agents Fluconazole (Diflucan)
Itraconazole (Sporanox)
Ketoconazole (Nizoral)
Voriconazole (Vfend)
HIV Drugs Amprenavir (Agenerase)
Atazanavir (Reyataz)
Delavirdine (Rescriptor)
Indinavir (Crixivan)
Nelfinavir (Viracept)
Ritonavir (Norvir)
Saquinavir (Invirase)
Miscellaneous Cyclosporine (Neoral)
HIV: human immunodeficiency virus
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dren who received open-label budesonide at a dose of
400 μg/day for 12 months [76]. Bacharier et al. also
found that long-term (3-year) treatment with budeso-
nide 400 μg/day had no significant effect on HPA-axis
function (as measured by standard-dose ACTH stimula-
tion testing and urinary cortisol excretion) in children
with mild-to-moderate asthma [77].
Few good-quality studies have compared the frequency
of AS among the various ICS formulations. In a
Cochrane review comparing beclomethasone, budeso-
nide and fluticasone, investigators were unable to make
any conclusions regarding the comparative safety of
these agents given the lack of available data [78]. How-
ever, other studies and meta-analyses have suggested
that there is increased suppression with high-dose fluti-
casone compared with other medications at equivalent
doses. A meta-analysis examining the systemic adverse
effects of fluticasone, budesonide, and beclomethasone
found marked biochemical evidence of AS at high ICS
doses (>750 μg/day of fluticasone, >1500 μg/day of
budesonide/beclomethasone). Fluticasone was found to
exhibit greater dose-related AS than the other ICS
therapies studied, particularly at doses above 800 μg/
day. The investigators concluded that this finding may
be due to the specific PK properties of fluticasone [79].
Unlike other ICS medications, ciclesonide appears to
have little or no suppressive effects on the HPA axis
[80]. Clinical studies of ciclesonide administered at
doses up to 640 μg/day have failed to show any signifi-
cant effects of this ICS on serum or 24-hour urinary
cortisol levels [81-83]. In a 12-week, double-blind, ran-
domized, placebo-controlled study comparing cicleso-
nide 320 μg/day OD or BID and 440 μg/day of
fluticasone TID to placebo, ciclesonide was associated
with peak cortisol levels (as assessed by both low- and
high-dose ACTH stimulation tests) and 24-hour urinary
free cortisol levels that were similar to those noted with
placebo. Fluticasone, on the other hand, was associated
with significant reductions in serum cortisol levels and
24-hour urinary free cortisol levels compared to placebo
[84]. In another study of 4 asthmatic children with AS
due to the use of inhaled fluticasone, normalization of
HPA-axis function was found after subjects were
switched to ciclesonide [23].
Clinical Evidence
With more than 60 case reports published in the litera-
ture, there is now strong clinical evidence supporting
the presence of ICS-associated AS [22]. The majority of
these cases have presented with signs of adrenal crisis,
particularly altered consciousness (seizure, coma) sec-
ondary to hypoglycemia, and had evidence of HPA-axis
suppression on testing. There are also case reports of
AS without crisis, including poor weight gain, poor lin-
ear growth or other non-specific symptoms. Almost all
cases have involved children being treated with ≥500
μg/day of fluticasone [17,26,85-88].
The largest series of case reports comes from a
national survey conducted in the UK, which identified
33 cases of AS (28 children and 5 adults). AS was con-
firmed with an ACTH stimulation test in the large
majority of cases (29) and by other measures of adrenal
function in the remaining 4 cases. All cases were treated
with high ICS doses (500-2000 μg/day). Despite the fact
that the vast majority with AS (91%) were receiving flu-
ticasone, only 16% of all patients were using fluticasone
in the UK at the time of this study. All but five children
presented with acute hypoglycemia characterized by sei-
zure, decreased levels of consciousness or coma; 1 death
was noted. The investigators concluded that the fre-
quency of acute adrenal crisis was greater than expected,
particularly in fluticasone-treated children [17].
Apart from exposure to illness or surgery, risk factors
for the development of adrenal crisis in children with
AS are not well understood. Therefore, increased aware-
ness and early recognition of AS are important to help
prevent against this potentially serious consequence of
ICS therapy.
Recommendations for the Prevention, Screening
and Management of Adrenal Suppression (AS)
As highlighted previously, AS often goes unrecognized
until physiologic stress precipitates an adrenal crisis. As
ar e s u l t ,t h ef r e q u e n c yo fA Si nt h ea s t h m ap o p u l a t i o n
is not well documented. Currently, there are no national
guidelines for AS screening in children with asthma.
Evidence suggests that screening approaches vary widely,
and that many children with asthma who are at risk for
AS are not screened. Guidelines in the UK state that the
use of fluticasone at doses ≥400 μg/day should be
accompanied with screening for AS [89]. Brodlie and
McKean investigated the screening practices of 14 ter-
tiary pediatric respiratory centres in the UK and found
that, despite these guidelines, less than 60% had an offi-
cial policy for screening children with asthma. The
investigators also found significant differences in the
threshold ICS dose used to start testing for AS, the type
of screening tests performed, and the interpretation of
test findings. In children prescribed fluticasone, 50% of
centres tested for AS at ≥500 μg/day, 21% at ≥1000 μg/
day and, in 29%, the cut-off dose for testing varied. For
beclomethasone, 50% of centres tested at ≥1000 μg/day,
14% at ≥1500-2000 mg/day and, in 36% of centres, var-
ious cut-off doses for testing were used. When consider-
ing AS testing, the use of oral prednisolone was taken
into consideration by less than 60% of centres. A low-
dose ACTH stimulation test was performed in 50% of
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measurement in only 8%; in 21% of centres, the screen-
ing test used varied. In total, only 57% of respondents
regarded AS as a significant problem [90].
Given these findings as well as the lack of published
guidelines for the prevention, screening and manage-
ment of AS, the authors have provided the recommen-
dations in this section based on the best available
literature and expert opinion.
Prevention
Although ICS therapy represents the mainstay of asthma
management, physicians and other healthcare profes-
sionals need to be aware of the risk for AS in all asthma
patients using ICS therapy, regardless of the dose pre-
scribed. Although most cases have been reported in indivi-
duals using high doses of fluticasone, a few cases have also
been noted in patients using low ICS doses [23,27,91].
Recognizing children at risk is imperative, and screen-
ing should be considered in any child with symptoms of
AS, children using high ICS doses, or those with a his-
tory of oral corticosteroid use (see Screening section for
more detail). Although poor growth is not always indi-
cative of AS, growth should be monitored every 6
months (ideally by using stadiometry measurements)
and measurements should be plotted on an appropriate
growth curve. If, after 6 months, growth velocity appears
to be inadequate, the physician should consider all pos-
sible etiologies, including AS, as well as referral to an
endocrinologist for appropriate testing.
Healthcare professionals should educate the parents of
children using high ICS doses about the risk of AS and
associated symptoms (see Table 2). Emergency contact
information should be provided to parents and care-
givers in the event of severe symptoms or suspected
adrenal crisis.
Most cases of adrenal crisis resulting from ICS therapy
have been associated with poor patient follow-up and
inappropriately high ICS doses [27]. Therefore, physi-
cians should regularly re-evaluate the child’s ICS dose to
ensure the lowest effective dose is utilized to control
asthma symptoms. Physicians should also consider clini-
cally important differences between ICS medications
(see section on PK and PD properties of ICS) as well as
the patient’s total steroid load (i.e., consider the use of
all forms of glucocorticoid therapy including oral,
inhaled, intranasal, intramuscular and intravenous). In
patients at risk of AS, consideration should be given to
the use of an ICS with minimal adrenal effects and the
best benefit-to-side effect ratio.
Screening
Screening is recommended in all children presenting
with symptoms of AS (including poor growth),
regardless of the ICS dose utilized (see Table 5). It
should also be considered in: (1) asymptomatic patients
who have been treated for 3-6 months with ≥500 μg/day
of fluticasone or ≥1000 μg/day of budesonide/beclo-
methasone; (2) children who have received a course of
oral corticosteroids for more than 2 consecutive weeks;
and (3) children who have received multiple courses of
oral steroids amounting to more than 3 weeks in the
last 6 months [24,27,53,61]. Although there is no evi-
dence and no case reports of AS with ciclesonide use,
the authors feel the safest approach at the present time
is to screen patients using over 1000 μg/day for 3-6
months. The authors also recommend screening all chil-
dren using concomitant ICS therapy and antiretroviral
or antifungal agents (e.g., itraconazole, ketoconazole,
voriconazole) since these potent CYP3A4 inhibitors can
potentiate the systemic side effects of ICS treatment.
Given the ease and practicality of a first morning cor-
tisol measurement, it should be considered for the initial
screening of these patients. The test should be per-
formed at 8:00 am or earlier given that cortisol levels
decline throughout the day with natural circadian
rhythm. For children receiving oral glucocorticoids, both
the evening and morning glucocorticoid doses should be
held prior to testing (see Table 5).
If the 8:00 am cortisol value is below the laboratory
normal, AS should be suspected and a referral to a
pediatric endocrinologist should be considered for con-
firmation of the diagnosis using the low-dose ACTH
test. A very low morning cortisol level (i.e., <85-112
nmol/L) is diagnostic of AS and warrants an urgent
referral to a pediatric endocrinologist. If the result is
within the laboratory normal range, the child should be
screened every 6 months. It is important to remember
that the sensitivity of a first morning cortisol measure-
ment is poor and, therefore, a normal value does not
rule out the presence of AS. If the child has a normal
test result, but symptoms of AS are present, a low-dose
ACTH stimulation test should be performed to confirm
the diagnosis.
Management
Whenever possible, cases of AS should be managed in
consultation with a pediatric endocrinologist. Daily
hydrocortisone at a physiologic dose (8-10 mg/m
2/day)
should be considered until the first morning cortisol
value normalizes (see Table 6). Dosing and timing of
daily glucocorticoid replacement should be discussed
with an endocrinologist. In all patients with proven AS,
stress steroid dosing (high doses of hydrocortisone) dur-
ing times of illness or surgery must be provided to
simulate the protective endogenous elevations in cortisol
levels that occur with physiological stress. For mild-to-
moderate illness, 20-30 mg/m
2/day of hydrocortisone,
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a cortisol level should be drawn immediately (to prove
suppression), the endocrinologist on call should be con-
tacted, and the child should be treated with an immedi-
ate stress dose of intravenous or intramuscular
hydrocortisone (100 mg/m
2), followed by 100 mg/m
2/
day of hydrocortisone, divided into 3 to 4 doses over a
24-hour period [22]. In patients on supraphysiological
doses of oral corticosteroids for more than 2 consecu-
tive weeks or those who have required more than 3
weeks of oral steroids over the course of 6 months,
tapering of steroids should be considered to allow for
adrenal recovery. In patients with proven AS, considera-
tion should also be given to the use of ciclesonide,
which has been shown to have little or no suppressive
effects on the HPA axis [80].
Parents and children at risk for AS should be educated
about stress steroid dosing and provided with emer-
gency medical contact information in the event of ill-
ness. Consideration should be given to providing
patients with a Medic-alert bracelet and/or information
card detailing their diagnosis, updated medication doses
and stress-dosing instructions.
Conclusions
In spite of the measurable effects of ICS therapy on the
HPA axis, it is important to remember that effective anti-
inflammatory therapy is essential for the treatment of
asthma, that ICSs are the most effective anti-inflamma-
tory agents available, and that the suppressive effects of
ICS therapy on the HPA axis is markedly less than clini-
cally equivalent doses of oral corticosteroids. At low-to-
moderate doses, ICS therapy does not present any signifi-
cant risk for systemic side effects. However, when high
doses are used for prolonged periods, serious adverse
events, including AS, are possible. The risk for AS can be
minimized through increased awareness and early recog-
nition of at-risk patients, regular patient follow-up to
ensure the lowest effective ICS doses are utilized, and by
choosing an ICS medication with minimal systemic
effects. When high-dose ICS therapy is required, impor-
tant differences in the PK and PD characteristics of the
available ICSs warrant consideration in clinical practice.
Table 5 Screening recommendations for AS
When to Screen? ► Patient has persistent symptoms of AS: Weakness/fatigue, malaise, nausea, vomiting, diarrhea, abdominal pain, headache
(usually in the morning), poor weight gain, myalgia, arthralgia, psychiatric symptom, poor growth, hypotension*,
hypoglycemia*
► Patient has been receiving high-dose ICS therapy for 3-6 months: ≥500 μg/day of fluticasone; ≥1000 μg/day of
budesonide/beclomethasone; or >1000 μg/day of ciclesonide
► Patient has received oral corticosteroids for: >2 consecutive weeks or >3 cumulative weeks in the last 6 months
► Patient using concomitant ICS therapy and potent CYP3A4 inhibitors, particularly antiretroviral and antifungal agents
► Complete first morning (08:00 am) cortisol test
- Must be completed by 8:00 am or earlier
- No oral glucocorticoids the evening and morning prior to the test
- Fasting not required
How to Screen? ► If result is normal, screen again in 6 months
► If result is normal but patient has symptoms of AS, perform low-dose ACTH stimulation test to confirm diagnosis:
-1μg of cosyntropin; cortisol levels taken at 0, 15-20 and 30 minutes
- Peak cortisol < 500 nmol/L = AS (peak >500 nmol/L is normal)
When to be
Concerned?
► 8:00 am cortisol value < 85 nmol/L = diagnosis of AS
► 8:00 am cortisol value < laboratory normal = possible AS; consider endocrinology referral for confirmation of diagnosis
AS: adrenal suppression; ICS: inhaled corticosteroid
*Symptoms of adrenal crisis require emergent management
Table 6 Recommendations for the management of AS
1. Stress steroids during periods of physiological stress
- Adrenal crisis: Hydrocortisone injection (Solu-Cortef) 100 mg/
m
2 (max. 100 mg) IV/IM stat with saline volume expansion,
followed by 25 mg/m
2 q 6 hours (max. 25 mg q 6 hours); call
endocrinologist on call
- Surgery: Hydrocortisone injection (Solu-Cortef) 50-100 mg/m
2
IV (max 100 mg) pre-operatively, then 25 mg/m
2 q 6 hours
(max 25 mg q 6 hours); call endocrinologist on call
- Illness or fever: 20 mg/m
2/day hydrocortisone equivalent,
divided BID or TID
- Fever >38.5
oC or vomiting: 30 mg/m
2/day hydrocortisone
equivalent, divided TID
- Unable to tolerate orally: Hydrocortisone must be
administered parenterally as Solu-Cortef, 25 mg/m
2/dose q 6
hours IV or q 8 hours IM
2. ± Daily physiologic dose of hydrocortisone (8-10 mg/m
2/day)
3. Family education
- Stress steroid dosing
- Emergency medical contact information in case of illness
4. Information card/Medic-Alert bracelet
IV: intravenous; IM: intramuscular; BID: twice daily; TID: three times daily; QID:
four times daily; q: every
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steroids during times of illness, injury or surgery are
imperative and will help reduce the morbidity associated
with this serious complication of ICS therapy.
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